Nations Financial Group
VRDN icon

Nations Financial Group’s Viridian Therapeutics VRDN Stock Holding History

Nations Financial Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$232K Hold
11,272
– – 0.01% 711
2026
Q2 		$207K Buy
+11,272
New +$182K 0.01% 752

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Nations Financial Group's VRDN Position: Q3 2026 in Review

Nations Financial Group held its Viridian Therapeutics (VRDN) position steady in Q3 2026 at 11,272 shares worth $232K. The position accounts for 0.01% of the portfolio, ranked #711.

Nations Financial Group first reported a position in VRDN in Q2 2026 and has held it in 2 quarters since. 94 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Nations Financial Group held 11,272 shares of Viridian Therapeutics worth $232K as of Q3 2026.
  • Nations Financial Group left its Viridian Therapeutics share count unchanged in Q3 2026.
  • Viridian Therapeutics made up 0.01% of Nations Financial Group's portfolio in Q3 2026, its #711 holding.
  • Nations Financial Group first reported a position in Viridian Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 94 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Nations Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.